NEW YORK — In this Healio Video Perspective from the ASRS meeting, Veeral S. Sheth, MD, MBA, FASRS, FACS, discusses phase 3 results from the Archway trial.
The trial examined central subfield thickness fluctuations in patients with neovascular age-related macular degeneration treated with the Port Delivery System with ranibizumab, now known as Susvimo.